Archives

DIF Capital Partners to divest its stakes in three Irish roads

DIF

DIF Capital Partners (“DIF”) is pleased to announce that DIF Infrastructure III (“DIF III”) has signed an agreement to sell its stakes in three Irish roads to Semperian PPP Investment Partners (“Semperian”).

The Irish roads portfolio consists of shareholdings in three projects that DIF invested into between 2013 and 2016: M3 Motorway, M4 Motorway and M50 Motorway. The M3 and M4 Motorway projects are demand-based toll roads and the M50 Motorway is an availability-based public private partnership. DIF has optimised these projects throughout its ownership and worked closely with the local management teams to successfully steer the roads through the Covid-19 pandemic. Traffic on the M3 and M4 Motorway projects has materially recovered in the last few months as lockdown restrictions have been lifted in Ireland. The sale of these assets means DIF III is almost fully divested as the end of the fund life approaches.

Andrew Freeman, Head of Exits at DIF: “We are very pleased with the sale of this high quality roads portfolio which delivers a strong exit outcome for our DIF III investors. We are confident that Semperian will be an excellent counterparty to the projects going forward given their extensive experience in managing these type of assets.”

DIF was advised on the transaction by Cantor Fitzgerald (financial), HSF (legal), Arthur Cox (Irish counsel), Jacobs (technical) and KPMG (tax & accounting).

Closing of the transaction is expected to take place in Q3 2022 subject to the receipt of customary approvals and consents.

About DIF Capital Partners

DIF Capital Partners is a leading global independent investment manager, with ca. EUR 10 billion in assets under management across nine closed-end infrastructure funds and several co-investment vehicles. DIF invests in infrastructure companies and assets located primarily in Europe, the Americas, and Australia through two complementary strategies:

  • DIF CIF funds, of which DIF CIF II is the latest vintage, target equity investments in small to mid-sized core-plus infrastructure companies in the telecom, energy transition, and transportation sectors.
  • Traditional DIF funds, of which DIF Infrastructure VI is the latest vintage, target core infrastructure equity investments with long-term contracted or regulated income streams including public-private partnerships, concessions, utilities, and energy transition projects (incl. renewable energy).

DIF Capital Partners has a team of over 190 professionals, based in eleven offices located in Amsterdam (Schiphol), Frankfurt, Helsinki, London, Luxembourg, Madrid, New York, Paris, Santiago, Sydney, and Toronto. For more information please visit www.dif.eu.

Contact: Thijs Verburg, t.verburg@dif.eu.

Categories: News

Tags:

CVC Credit supports Altano Group’s buy and build plans

CVC Credit to provide debt facilities supporting acquisitive growth strategy of leading European equine veterinary clinic network

CVC Credit is pleased to announce that it has provided debt facilities to support the acquisitive growth strategy of Altano Gruppe (“Altano”), a leading network of equine veterinary clinics and practices across Europe. CVC Credit will support the continuing growth strategy of the business through its European Direct Lending Strategy, which focuses on lending to established European medium and large companies with proven business models.

Headquartered in Germany, Altano is the leading consolidator and operator of equine veterinary clinics services with over 350 vets based across 40 locations in six European countries, including Germany, France, Netherlands, Belgium, Sweden, and Denmark. The company provides a wide range of diagnostic and therapeutic services to more than 100,000 customers per year, including routine services, internal medicines and orthopaedics.

David Deregowski, Director in the Private Credit team at CVC Credit, added: “Over the past five years this business has developed into one of the leading providers of equine veterinary services in Europe, with an expansive network and fantastic team. We are impressed by their track record of organic and acquisition-led growth and are pleased to support its experienced management team as they look to scale the company further.”

Andrew Davies, Partner and Co-Head of Private Credit at CVC Credit, said: “Our ability to draw on the local presence and sector specialisms of CVC’s European office network and sector teams is a true differentiator. In this case the experience of CVC Germany and CVC’s Healthcare team were invaluable in swiftly conducting diligence, pricing and winning this opportunity.”

Dr. Victor Baltus, Managing Director of Altano Gruppe, said: “We are happy to have completed the refinancing of the business and secured financing to continue to execute our acquisition growth strategy. This strong foundation and the support of Ufenau Capital Partners and CVC Credit will allow us to progress with our next phase of development.”

Kevin Elsaesser, Investment Manager at Ufenau Capital Partners commented: “We are pleased and excited to bring CVC Credit onboard. Their understanding of the market dynamics and Altano’s operating model was impressive. Together with their experience in supporting growth strategies of similar business, we are convinced that they will have a key role in the business’s international expansion.”

Categories: News

EQT AB establishes Sustainability Committee, marking the first Board-level commitment to sustainability in the private markets industry

eqt
Sustainability is a core part of EQT’s strategic agenda. To further elevate EQT’s strategic direction and its ability to make a positive impact at scale, the Board of EQT AB has established a Sustainability Committee.
The Sustainability Committee marks the first of its kind in the private capital space dedicated to sustainability at the Board level. This follows EQT becoming the first private markets firm to set Science Based Targets in 2021, further reinforcing the firm’s leadership position in sustainability. The Committee will provide a platform for debate on EQT’s sustainability agenda between the Board and Management, uniquely positioning the firm to deliver long-term performance for its clients.

Through quarterly meetings, the Committee will formalize ongoing discourse between Management and the Board to challenge the firm’s sustainability strategy in the context of an ever-evolving environment. The Committee will also welcome external thought leaders across different areas to enrich EQT’s approach towards accelerating specific sustainability themes, ultimately ensuring that EQT continues to stay ahead of the curve. Collectively, these mechanisms will enable EQT to strengthen the sustainability mandate of the Board, and to future-proof the firm in line with forthcoming sustainability trends.

Nicola Kimm, Board member of EQT AB since 2020, will be the Chairperson of the Committee. Nicola is the Chief Sustainability Officer and Management Board member at Heidelberg Cement, previously having been Global Head of Sustainability, Environment, Health and Safety at Signify.

Other Committee members include EQT AB’s Chairperson Conni Jonsson and Board member Margo Cook, who was elected last year. Margo is a former President of US based Nuveen Advisory Services, one of the world’s largest asset managers with USD 1 trillion in assets under management and USD 46.3 billion in assets under management with specific responsible investing objectives.

Nicola Kimm, Board member of EQT AB, said, “The role of the Sustainability Committee will be to ensure that EQT remains ahead of the curve and lead the transformation of private markets. By continuously raising the bar for EQT’s sustainability agenda, we also challenge and raise the inherent impact potential of the industry.”

Bahare Haghshenas, Global Head of Sustainable Transformation at EQT, said, “As a purpose-driven and active owner, sustainable transformation is at the core of our strategy. Having a dedicated Committee supporting this journey will further strengthen alignment between the Board and Management and will encourage us to think long-term, ultimately accelerating our efforts to drive superior returns for our clients in the most responsible way.”

Contact
Bahare Haghshenas, Head of Sustainable Transformation, +45 31 31 04 31
Rickard Buch, Managing Director, Communications, +46 72 989 09 11
EQT Press Office, press@eqtpartners.com, +46 8 506 55 334

Categories: News

CapMan to publish its 1–3 2022 Interim Report on Thursday 28 April 2022

Capman

CapMan Plc press release
22 April 2022 at 9.00 a.m. EEST

CapMan to publish its 1–3 2022 Interim Report on Thursday 28 April 2022

CapMan will publish its Interim Report for the period 1 January–31 March 2022 on Thursday 28 April 2022 around 8.00 a.m. EEST. The company will present the results for the review period over a webcast press conference starting at 9.30 a.m. EEST accessible at https://capman.videosync.fi/2022-q1-results. The conference will be held in English. The report and presentation material will be available at CapMan’s website after the publication (https://www.capman.com/shareholders/financial-reports/).

For further information, please contact:
Linda Tierala, Director, Communications and IR, tel. +358 40 571 7895, linda.tierala@capman.com

Webcast:
28 April 2022 at 9.30 a.m. EEST
https://capman.videosync.fi/2022-q1-results
About CapMan
CapMan is a leading Nordic private asset expert with an active approach to value creation. As one of the private equity pioneers in the Nordics we have built value in unlisted businesses, real estate, and infrastructure for over three decades. With over to €4.5 billion in assets under management, our objective is to provide attractive returns and innovative solutions to investors. We are dedicated to set science-based targets to reduce our greenhouse gas emissions in line with the Paris Agreement. We have a broad presence in the unlisted market through our local and specialised teams. Our investment strategies cover minority and majority investments in portfolio companies and real estate, and infrastructure assets. We also provide wealth management solutions. Our service business includes procurement and analysis, reporting and back office services. Altogether, CapMan employs approximately 160 professionals in Helsinki, Stockholm, Copenhagen, Oslo, London and Luxembourg. We are listed on Nasdaq Helsinki since 2001. Read more at www.capman.com. 

Categories: News

Gimv invests in BioConnection, a contract development and manufacturing organisation for injectable (bio)pharmaceutical products

GIMV

Topic: Investment

Gimv invests in BioConnection alongside current shareholders Pharming Group, Mibiton and management with the aim to accelerate the next stage of growth, and to facilitate further innovation in order to continue offering the best quality services to clients. The BOM has supported BioConnection since inception and has sold its shares.

BioConnection is a niche contract development and manufacturing organisation (CDMO) focused on fill and finish and freeze-drying of injectable (bio)pharmaceutical products The company operates from its FDA & GMP approved manufacturing site in Oss (NL) and is one of the few niche players with both clinical and commercial manufacturing capabilities.

BioConnection operates in the fast-growing aseptic fill & finish market, which is a specialised type of manufacturing for (liquid) final dosage form of drugs requiring an aseptic environment, high quality equipment, and freeze-drying expertise. Especially freeze drying requires specialised expertise, as it is a highly complex technology that stabilises drugs and improves shelf-life (reducing waste and improving access to medicine). Accordingly, (bio)pharmaceutical companies increasingly rely on BioConnection for these services, due to BioConnection’s expertise, infrastructure and flexible set-up (providing tailored offering).

Due to the fast growing (bio)pharmaceutical industry, the growing capacity shortage in the whole sector, and the shift towards outsourced production for pharmaceutical companies, the position of CDMOs has become even more important. In order for BioConnection to keep providing the highest quality service to its customers, significant investments are foreseen for the coming period. Investments will be made to improve the overall production capacity, to further increase the flexibility of production, to remain fully compliant with the constantly increasing regulatory demands and to insource additional services such as formulation, analytical testing and packaging.

Together with the co-shareholders Pharming Group, Mibiton and management, Gimv looks forward to supporting BioConnection in its next growth phase by further investing in the organisation and infrastructure to increase the production capacity and to further extend services to customers. Furthermore, Gimv will leverage its life sciences network to further support BioConnection.

Elderd Land, Partner at Gimv, states: “We are very impressed by what Alexander and his team have built over the last decade. The quality of the facilities, the ability to serve and grow at small and medium sized companies and the contribution to the overall development in the pharma space (i.e. personalised medicine) is unparalleled in this size bracket. We are very much looking forward to supporting BioConnection through its next growth phase and to continuing to build this already leading company.”

Alexander Willemse, CEO of BioConnection, says: “We are happy to have found a partner for the next stage of BioConnection. With the new shareholding structure BioConnection is able to fund and further develop our people, infrastructure and service offering. This enables us to fulfil the needs of innovative (bio)pharmaceutical companies by offering the highest quality CDMO services on the market.”

 

Read the full document

English – French – Dutch
 

Gimv

Karel Oomsstraat 37, 2018 Antwerpen, Belgium

www.gimv.com

Categories: News

Tags:

EQT- Earth Day Message from the CEO

eqt
In honor of Earth Day, I would like to update you on EQT’s commitment to tackling climate change. In March, I participated in a forum with a group of global business leaders, discussing how we can best address the issues surrounding climate change. With every conversation, one prevailing theme was evident to everyone: the need for urgent environmental action is increasing by the hour, and we all have our part to play.
The most recent International Panel on Climate Change (IPCC) report has made painfully clear the level of action necessary to begin to change that incoming tide that is climate change, with the report stating that limiting global warming to 1.5°C requires us to reach peak greenhouse gas (GHG) emissions by 2025 at the latest. Failure to do so will lead to severe human exposure to extreme weather events, acute food and water insecurity, mass mortalities of natural habitats and biodiversity loss.

The private capital industry is uniquely positioned, due to its governance model and the capital at disposal, to address some of the challenges we are facing today and to help build a better future. At EQT, this is at the heart of our approach as we focus on having a positive impact through our active ownership model. This approach enables our team to invest behind thematic mega-trends, future-proof companies and accelerate the sustainable transformation that is required across all industries and sectors.

The private capital industry also has a critical role in increasing capital flows to businesses providing innovative solutions to environmental challenges. Society needs to contribute approximately USD 90 trillion of investments in the coming 15 years (IPCC) to close the net zero funding gap.

On our side, EQT has invested more than EUR10bn over the last 12 months in climate and environmentally-oriented companies. Our recent investments in firms like Covanta, Cypress Creek Renewables, Oterra, Instavolt and Vinted, among many others, have created industry leaders in e.g. waste management, renewable energy supply and circularity. This is a good starting point, but there is a journey that every firm must participate in if we are to limit the effects of climate change.

We have recently committed all our portfolio companies to achieving net zero by 2040, ten years faster than required by climate science. This ambition covers Scope 1-3 GHG emissions for both EQT AB and our investments, and aims to follow the required 45 percent reduction in GHG emissions by 2030. Already more than 40 of EQT’s portfolio companies have started their explicit journeys towards net zero. To successfully achieve this, we are collaborating with leading institutions – including the Science Based Targets initiative (SBTi) and our peers – on defining net zero standards for financial institutions, drawing on the expertise of leading third-party specialists.

To ensure we hold ourselves accountable, we have undertaken measures to tie environmental performance to financial incentives through EQT AB’s EUR 2 billion of sustainability-linked bond issuances, and intend to further drive behavioral change through sustainability-linked mechanisms and personnel bonuses. Whilst decarbonisation needs to be the first priority, we are also proponents of carbon removal investments to support critical carbon capture & storage innovation. EQT AB’s 2021 GHG footprint was balanced with best-in-class carbon removal and storage projects, priced at >EUR100 per metric tonne of CO2.

Looking ahead, it is clear that environmental inaction is likely to drive severe social and economic instability on a global scale. We need to act now – together with customers, peers, suppliers, shareholders and regulators. We need to continue to transform the way we do business, support climate innovation and accelerate our partnerships in a joint and collaborative effort. We believe that investing in a positive future will also secure the best financial returns for our clients.

Through EQT’s active ownership model and our strong sense of community, I am confident we can help solve some of society’s most pressing problems.

Christian Sinding
CEO, EQT
Contact
Bahare Haghshenas, Head of Sustainable Transformation, +45 31 31 04 31
Rickard Buch, Managing Director, Communications, +46 72 989 09 11
EQT Press Office, press@eqtpartners.com, +46 8 506 55 334

Categories: News

Ardian raises record $5.25bn infrastructure secondaries fund

Ardian

The world’s largest infrastructure secondaries fund to-date demonstrates the strength of Ardian’s platform and the growth of infrastructure secondaries as an asset class.

Ardian, a world-leading private investment house, today announces it has raised $5.25bn for its latest infrastructure secondaries fund – Ardian Secondary Fund VIII Infrastructure (ASF VIII Infrastructure). The fund, which was significantly oversubscribed and reached its hard cap within nine months, is the largest infrastructure secondaries platform in the world. It represents a more than 3x increase from the previous generation raised in 2017.

The successful fundraise is the latest of a number of innovations developed by Ardian’s secondary platform in its 23 year history. The team, led by Mark Benedetti, Vladimir Colas, Marie-Victoire Rozé and Jan Philipp Schmitz, now comprises over 110 investment professionals who continuously engage with General Partners, sellers, and clients to develop innovative solutions to investors‘ liquidity needs. Ardian’s secondary AUM has increased by $8 billion to $63 billion in the last 12 months.

The ASF VIII Infrastructure platform attracted over 145 investors from 28 countries across the Americas, Europe, Asia, and the Middle East, comprising major pension funds, insurance companies, HNWIs and financial institutions.

The fundraise demonstrates strong investor appetite in a secondary market that is poised to grow significantly in the coming years on the back of increasing investor demand for private market investments. Secondary buyers provide an important source of liquidity for investors around the world whose allocations to private markets are becoming more significant in their portfolios. Ardian continues to lead the market in infrastructure secondaries having recently completed the two largest infrastructure secondary transactions in the world.

Continuing its successful investment strategy, ASF VIII Infrastructure will focus on high quality infrastructure funds and assets, managed by blue chip general partners in North America and Europe. The fund is targeting a diverse range of underlying assets, from renewable energy and telecoms to transport and utilities. Sustainability is embedded at every step of Ardian’s investment and portfolio monitoring approach.

The fund is already 30% committed in two infrastructure secondary transactions, including one of the largest secondary infrastructure transactions ever completed, a diversified portfolio of over 30 infrastructure funds and co-investments purchased from a financial institution.

Ardian Secondaries

Ardian Secondaries is the world’s largest Fund of Funds platform.

The successful fundraise follows a record year for Ardian’s Secondaries team in 2021, closing 27 transactions which represent $17 billion in deal volume. The average deal size for the top 10 transactions was $1 billion.
Over the past 12 months, Ardian’s Secondaries business increased its AUM by $8 billion to $63 billion. The team’s headcount also grew by 22% in 2021, now comprising more than 110 investment professionals.

ABOUT ARDIAN

Ardian is a world-leading private investment house with assets of US$125 billion managed or advised in Europe, the Americas and Asia. The company is majority-owned by its employees. It keeps entrepreneurship at its heart and focuses on delivering excellent investment performance to its global investor base. Through its commitment to shared outcomes for all stakeholders, Ardian’s activities fuel individual, corporate and economic growth around the world. Holding close its core values of excellence, loyalty and entrepreneurship, Ardian maintains a truly global network, with more than 800 employees working from fifteen offices across Europe (Frankfurt, Jersey, London, Luxembourg, Madrid, Milan, Paris and Zurich), the Americas (New York, San Francisco and Santiago) and Asia (Beijing, Singapore, Tokyo and Seoul). It manages funds on behalf of more than 1,200 clients through five pillars of investment expertise: Secondaries, Direct Funds, Infrastructure, Real Estate and Private Debt.

www.ardian.com

Media Contacts

ARDIAN

HEADLAND CONSULTANCY

ardian@headlandconsultancy.com  

Categories: News

American Laboratory Products Company Merges with GeneProof

Ampersand

SALEM, N.H. and BRNO, Czech Republic, April 21, 2022 /PRNewswire/ — American Laboratory Products Company, Ltd. (“ALPCO”), a specialty in vitro diagnostics company, today announced a merger with GeneProof a.s. (“GeneProof”), a leading molecular diagnostics company based in Brno, Czech Republic. The combination creates a global market leader in the diagnostic products market, with broad capabilities spanning novel immunoassay testing kits, real-time PCR testing products, and automated laboratory instrumentation solutions.

GeneProof was founded over 15 years ago by Drs. Radek Horvath and Milos Dendis and is an established market leader in the molecular diagnostics field. Both Founders will remain with the merged company and continue as significant shareholders. GeneProof is the largest producer of PCR reagents in the Czech Republic and distributes its portfolio of more than 70 CE-marked molecular diagnostic tests and instruments throughout Europe, Africa, the Middle East, and South America. Products are primarily focused on the infectious and genetic diseases. With a strong emphasis on quality, GeneProof offers technologically advanced real-time PCR kits and user-friendly automated instrument platforms for both nucleic acid extraction and sample-to-answer testing that meet the diverse throughput needs of laboratories.

The combined company is majority owned by Ampersand Capital Partners (“Ampersand”), which first invested in ALPCO in 2020.

“ALPCO and GeneProof have both earned great reputations in their respective markets, ALPCO in immunodiagnostics and GeneProof in molecular diagnostics,” said Sean Conley, President and CEO of ALPCO. “The combination of the two companies transforms both organizations into a more complete solutions provider and aligns well with ALPCO’s strategy of investing in proprietary automated platforms.”

Radek Horvath, CEO of GeneProof, added, “This strategic connection represents a new chapter in the life of both companies. It will facilitate the entry of GeneProof products into the US market, and similarly, expand the presence of ALPCO products into the EU and around the world. The combination of deep knowledge in the field of molecular diagnostics as well as in the field of immunological diagnostics will bring a significant synergistic effect. The two merged companies intend to use each other’s technological experience and rely on the support of our strong partner, Ampersand, for further development.”

Eric Lev, General Partner at Ampersand and Board member of ALPCO added, “I look forward to working with Sean, Radek, and Milos as we build the combined company into a fully integrated global leader in the field of diagnostics and commercialize GeneProof’s fully automated real-time PCR offerings in the North American market.”

About ALPCO

American Laboratory Products Company (ALPCO) was founded in 1991 as an importer and distributor of immunoassay-based products for the North American life science markets. The company has since evolved into a leading producer of novel immunodiagnostic reagents for specialty testing laboratories. In September of 2020, ALPCO announced the recapitalization of the company by Ampersand Capital Partners. Ampersand’s investment was sought to accelerate ALPCO’s global growth initiatives, including the expansion of the company’s diagnostics reagent offering, broadening the company’s geographic presence, and fueling technological advancement. For additional information, please visit www.alpco.com.

About GeneProof

Based in Brno, Czech Republic, GeneProof a.s. was founded in 2005 by Dr. Radek Horvath and Dr. Milos Dendis. GeneProof offers a wide range of in vitro molecular diagnostic products, primarily focused on the infectious diseases and genetic mutations. The Company has established a portfolio of more than 70 CE-marked PCR test kits and a proprietary instrumentation offering to serve laboratories of all sizes. GeneProof’s sales and distribution network covers more than 60 countries around the world. For detailed information see www.geneproof.com.

About Ampersand Capital Partners

Founded in 1988, Ampersand is a middle market private equity firm with more than $2 billion of assets under management dedicated to growth-oriented investments in the healthcare sector. With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm’s core healthcare sectors. Additional information about Ampersand is available at ampersandcapital.com.

Categories: News

Tags:

Mendel Raises $40 Million Series B Round to Expand its Team and Grow Product Offering

Dcm Ventures

SAN JOSE, Calif., April 21, 2022 /PRNewswire/ — Mendel, the leading clinical artificial intelligence and natural language processing platform, today announced it has raised $40 million in Series B funding round led by Oak HC/FT. The round includes participation from existing investor DCM, who led Mendel’s Series A funding round in June 2021.

This funding comes amidst surging customer demand for Mendel’s AI infrastructure. The fresh capital will enable the company to expand its team of AI and engineering teams and scale the commercial organization. It will also help accelerate the release of Mendel’s new, breakthrough product, Resolve, which consolidates clinical information to create a coherent longitudinal view of the patient journey. Traditionally, it takes nearly five years to manually abstract 2 million patient lives. Mendel’s Resolve abstracts the same number in less than 24 hours.

“The capital we have raised is a testament to the strong market fit and demand,” said Karim Galil, Co-Founder and CEO of Mendel. “Our vision it to weave Mendel into the fabric of every healthcare data platform. It’s exciting to partner with Oak HC/FT as we enable the healthcare ecosystem to provide better care for every patient.”

The healthcare industry faces immense challenges in parsing unstructured medical data that is highly valuable, but also extremely difficult and expensive to access. Mendel’s solution unlocks 80% of the world’s clinical data by leveraging contextual understanding to transform unstructured electronic medical record (EMR) data and clinical literature into comprehensive and compliant analytics-ready data. It abstracts data 27,000 times faster than the primarily manual methods most frequently used in clinical settings, and its output is reviewed and validated by a team of clinical experts to guarantee research-grade output.

“We believe Mendel can become a mission-critical infrastructure platform for the healthcare industry,” said Billy Deitch, Partner at Oak HC/FT. “Mendel’s technology sets a new standard in accuracy and scalability for processing unstructured medical data and we are confident that the company will continue to lead the industry with cutting edge solutions [and delivering for their customers].”

“Going as far back as our first investment in 2017, we’ve always known that Mendel’s novel AI technology was going to change the face of healthcare’s information infrastructure,” said Hurst Lin, General Partner at DCM. “We’re proud to continue to support Mendel through its next phase of growth that comes at such a critical time for the entire healthcare industry.”

For more information about Mendel visit Mendel.ai, and to see open positions visit Mendel.ai/careers.

About Mendel
Mendel is a machine that can read and understand medicine. Mendel Health is a for-profit corporation headquartered in San Jose, California that uses novel AI technology to absorb clinical data in medical literature as well as patient health records, to unlock a wide range of Real World Data applications. For more information about Mendel, visit Mendel.ai.

About OAK HC/FT 
Oak HC/FT is a venture and growth equity firm investing in companies driving transformation in healthcare and fintech, two uniquely complementary and high-growth sectors. With deep domain expertise and strategic resources, Oak HC/FT partners with leading entrepreneurs at every stage, from seed to growth, to build businesses that make a measurable, lasting impact on these industries. Founded in 2014, the firm has $3.3 billion in assets under management and is headquartered in Greenwich, CT, with investors in San Francisco and Boston. Follow Oak HC/FT on Twitter and LinkedIn and learn more at oakhcft.com.

About DCM
DCM is a global venture capital firm based in Silicon Valley, Beijing and Tokyo with over $4.2 billion under management and a 25-year track record of top performance. DCM has invested in more than 400 early-stage technology companies globally and provides hands-on operational guidance and a global network of business and financial resources. DCM portfolio companies have an aggregate enterprise value exceeding $250 billion including industry leading companies Bill.com, Careem (UBER), Hims & Hers, Kuaishou, Musically (TikTok) and SoFi. For more information, visit https://www.dcm.com.

Media Contact:
Amalia Lytle
646-818-9271

Categories: News

Tags:

AURELIUS GROUP JOINS UN GLOBAL COMPACT INITIATIVE

Aurelius Capital

Munich, 21. April 2022 – AURELIUS Group has joined the UN Global Compact (UNGC) and its German subsidiary, Deutsches Global Compact Netzwerk (DGCN). The membership underlines AURELIUS´ commitment to Environmental, Social and Governance (ESG) values within everyday practice and complements the Group’s participation at the UN PRI network in December 2021.

The UN Global Compact is the world’s largest and most important initiative for sustainable and responsible corporate governance, globally connecting more than 19,000 companies and organisations. The German subsidiary DGCN has more than 780 participants across business, civil society and politics. The UNGC supports companies in strategically incorporating sustainability values based on ten universal principles and in contributing to the implementation of the Sustainable Development Goals. In line with the UNGC, AURELIUS commits to the initiative´s ten principles, which are assigned to the categories: Human Rights, Labour, Environment and Anti-Corruption.

“Walk the talk – there are not many economic fields where this saying is as resonating as it is with ESG. At AURELIUS, we are not only fully committed to supporting the UNGC´s values – we are also deeply convinced that our organisation and our people can contribute a small piece to the initiatives vision. Joining the UNGC and DGCN is a logical step for us and is aligned with our core values”, stated Matthias Täubl, AURELIUS CEO.

As an official member of UNGC and DGCN, AURELIUS will proudly integrate the principles into its corporate culture and strategy. They will be promoted in the best possible way within day-to-day operation.

Categories: News

Tags: